26 September 2020
: Case report 
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus
Unusual clinical course, Diagnostic / therapeutic accidents, Unusual setting of medical care, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
María Fernanda Zurita1BDEF, Adriana Iglesias Arreaga1BEF*, Adriana A Luzuriaga Chavez1F, Luis Zurita2ABDFDOI: 10.12659/AJCR.927304
Am J Case Rep 2020; 21:e927304
Table 2. Clinical characteristics and laboratory values for lupus patients with COVID-19.
| Characteristics | n=5 (%) |
|---|---|
| Fever | 3 (60) |
| Chills | 1 (20) |
| Dry cough | 2 (40) |
| Chest pain | 3 (60) |
| Dyspnea | 2 (40) |
| Hypogeusia | 2 (40) |
| Anosmia | 2 (40) |
| Odynophagia | 2 (40) |
| Asthenia | 3 (60) |
| Myalgias | 2 (40) |
| Diarrhea | 1 (20) |
| Headache | 1 (20) |
| Polymerase chain reaction (PCR) | 5 (100) |
| Positive PCR on admission | 0 (0) |
| Negative PCR on admission | 0 (0) |
| Positive PCR at discharge | 5 (100) |
| Negative PCR at discharge | 5 (100) |
| Immunoassay: COVID-19 IgG/IgM Rapid test | |
| Leukopenia (<4000 μl) | 2 (40) |
| Lymphopenia (<1500/μl) | 5 (100) |
| Thrombocytopenia (<150×10/L) | 1 (20) |
| Lactate dehydrogenase (LDH) | |
| LDH: Within normal range (<250 U/l) | 5 (100) |
| LDH: Moderately increased (250–500 U/l) | 0 (0) |
| LDH: Highly increased (>500 U/l) | 0 (0) |
| Ferritin | |
| Normal value (10–150 ng/ml) | 5 (100) |
| Above the upper limit | 0 (100) |
| Procalcitonin | |
| Normal value (<0.5 ng/ml) | 5 (100) |
| Abnormal value (>0.5 ng/ml) | 0 (0) |
| Interleukin 6 | |
| Normal value (<6.00 pg/mL) | 3 (60) |
| Abnormal value (>6.00 pg/mL) | 2 (40) |
| Positive D-dimer (>250 ng/mL) | 1 (20) |
| Normal | 4 (80) |
| Abnormal | 0 (0) |
| Normal | 4 (80) |
| Abnormal | 1 (20) |
| Chest CT findings – chest computed tomography findings. * Patient had a ground-glass opacity (GGO) on the CT. | |